Nyu Langone Health

This study tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 patients enrolled before the trial was stopped early. The goal was to see how many…